Qiagen
(
QGEN">QGEN
), a major provider of innovative technologies and products for
pre-analytical sample preparation and molecular diagnostics
solutions, recently introduced itsQIAensemble Decapper automation
system.
This is an open platform system with which laboratories can
eliminate many manual steps needed for the management of
liquid-based cytology and other liquid vials. The rollout
ofQIAensemble Decapper is underway in Europe and other parts of the
world.
TheQIAensemble Decapper automation system, operated by an
improved graphical user interface (GUI), is path-breaking as it
will support downstream molecular testing while minimizing the
chances of injuries to laboratory staff from repetitive motions.
This system is compatible with sample racks on theQIAsymphony SP
automation system.
Further, it regulates the processing with digital data
collection and is flexible in regard to output tube types, such as
conical tubes, u-shaped tubes, BDVacutainer tu bes andGreiner's
Vacuette tubes.
Companion diagnostics are currently gaining significant traction
and peers ofQiagen like
Myriad Genetics
(
MYGN">MYGN
) are establishing themselves as strong players in this market.
However,Qiagen's long-term strategy involves technological
advancement and new product introduction that can hugely increase
its competitive advantage.
The company is constantly endeavoring for timely development and
launch of products that address growing market needs. Currently,
other than its next generation high throughput molecular
testingQIAensemble product platform,Qiagen has several products
underway like molecular medium-throughputQIAsymphony platform and
related sample and assay technologies.
Moreover,Qiagen has historically expanded its reach and
technological portfolio through acquisitions and is looking to ramp
up investment in the future. The company's recent acquisitions of
Australia-basedCellestis and France-basedIpsogen are expected to
strengthenQiagen's leadership in molecular diagnostics,
significantly expanding its profiling and personalized healthcare
portfolios.
Additionally, we are also encouraged byQiagen's efforts on
partnering with the pharmaceutical industry. In September
2011,Qiagen entered into a partnership with
Eli Lilly
(
LLY">LLY
) to jointly develop, manufacture and commercialize a molecular
companion diagnostic for an early-stage investigational compound,
which is currently being developed by Lilly. We strongly believe
thatQiagen's aggressive acquisition and collaboration strategies
will help drive growth in fiscal 2012 and beyond.
Currently,Qiagen retains aZacks #3 Rank (short-term Hold). Over the
long term, we remain Neutral on the stock.
LILLY ELI & CO (
LLY
): Free Stock Analysis Report
MYRIAD GENETICS (
MYGN
): Free Stock Analysis Report
QIAGEN NV (
QGEN
): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment
Research